Effective treatment of apatinib for chemotherapy‑refractory advanced gastric carcinoma with AFP‑secretion and HER2‑positivity: A case report
- Authors:
- Published online on: June 2, 2021 https://doi.org/10.3892/mco.2021.2313
- Article Number: 151
-
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
α‑fetoprotein (AFP)‑secreting gastric cancer (AFP‑GC) is a relatively rare, aggressive malignancy among all GC types. However, no GC case with simultaneous expression of AFP and epidermal growth factor receptor 2 (HER2) has been reported to date. To the best of our knowledge, the present report was the first to describe the use of apatinib to treat a patient with advanced GC characterized by AFP‑secretion and HER2‑positivity. An 86‑year‑old man with advanced GC was diagnosed with AFP‑secretive and HER2‑positive GC with liver metastasis at The Affiliated Hospital of Jiujiang University (Jiujiang, China). The patient received first‑line (i.e., S‑1 plus oxaliplatin) and second‑line (i.e., docetaxel) chemotherapy combined with trastuzumab for two cycles, respectively. However, the disease progressed rapidly. Subsequently, apatinib was administered as third‑line therapy. After two cycles of apatinib therapy, the patient reported the disappearance of upper abdominal pain and an improvement in his appetite. Furthermore, the AFP level had sharply decreased to 620 ng/ml. Subsequently, upper abdominal computed tomography imaging revealed that the gastric lesion and liver metastatic lesion had reduced in size by 67% and 24%, respectively, suggesting partial remission. Currently, the patient has continued to receive apatinib therapy. It was speculated that AFP‑secretion status could contribute to the chemoresistance of HER2‑positive GC. Apatinib may be a promising anticancer agent in the case of advanced AFP‑producing and HER2‑positive GC.
